- Home
- ROIV vs MASI Comparison
ROIV vs MASI Comparison
Compare ROIV & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | MASI |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 9.2B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ROIV | MASI |
|---|---|---|
| Price | $27.53 | $178.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | $27.56 | ★ $184.00 |
| AVG Volume (30 Days) | ★ 4.4M | 1.6M |
| Earning Date | 02-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.05 |
| EPS | ★ N/A | N/A |
| Revenue | $29,053,000.00 | ★ $1,239,153,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | $594.84 | $7.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.34 |
| 52 Week Low | $8.91 | $125.94 |
| 52 Week High | $30.33 | $179.00 |
Technical Indicators
Market Signals| Indicator | ROIV | MASI |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 71.81 |
| Support Level | $26.45 | $176.68 |
| Resistance Level | $27.94 | $179.00 |
| Average True Range (ATR) | 0.96 | 0.92 |
| MACD | -0.08 | -0.89 |
| Stochastic Oscillator | 62.10 | 82.13 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MASI Masimo Corporation
Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.